Phio Pharmaceuticals Corp. financial data

Symbol
PHIO on Nasdaq
Industry
Pharmaceutical Preparations
Location
11 Apex Drive, Suite 300 A, Pmb 2006, Marlborough, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
RXi Pharmaceuticals Corp (to 11/14/2018)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 513 % +7.51%
Debt-to-equity 27.2 % +64%
Return On Equity -135 % -1.73%
Return On Assets -108 % -3.07%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.06M shares -56.8%
Common Stock, Shares, Outstanding 958K shares -58.5%
Entity Public Float 5.7M USD -40%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 990K shares +265%
Weighted Average Number of Shares Outstanding, Diluted 990K shares +265%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.67M USD -47.2%
General and Administrative Expense 3.82M USD -19%
Operating Income (Loss) -7.61M USD +34.7%
Nonoperating Income (Expense) 193K USD
Net Income (Loss) Attributable to Parent -7.42M USD +36.4%
Earnings Per Share, Basic 15.8 USD/shares +85%
Earnings Per Share, Diluted 15.8 USD/shares +85%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.39M USD -35.9%
Assets, Current 5.86M USD -37.1%
Property, Plant and Equipment, Net 1K USD -99.3%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 5.87M USD -38.5%
Accounts Payable, Current 184K USD +6.36%
Employee-related Liabilities, Current 222K USD -45.6%
Accrued Liabilities, Current 735K USD -64.7%
Liabilities, Current 919K USD -60.5%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 1.63M USD -17.2%
Retained Earnings (Accumulated Deficit) -145M USD -5.4%
Stockholders' Equity Attributable to Parent 4.95M USD -31.4%
Liabilities and Equity 5.87M USD -38.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.01M USD +25.7%
Net Cash Provided by (Used in) Financing Activities -4M USD -10426%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 958K shares -58.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.39M USD -36.3%
Deferred Tax Assets, Valuation Allowance 2.55M USD -84.9%
Deferred Tax Assets, Gross 2.56M USD -84.9%
Operating Lease, Liability 0 USD -100%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 35K USD -80%
Property, Plant and Equipment, Gross 1.14M USD -15.9%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 35K USD -75%
Lessee, Operating Lease, Liability, to be Paid, Year One 35K USD -75%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -106%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Three 35K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 774K USD -93.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares +900%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 105K USD -23.4%
Additional Paid in Capital 150M USD +3.57%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1K USD -93.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%